Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis

Modern Rheumatology

Volumn 26, Issue 3, 2016, Pages 454-457

  Sumida, Hayakazu ^a   Asano, Yoshihide ^a   Hatano, Masaru ^b   Aozasa, Naohiko ^a   Toyama, Tetsuo ^a   Akamata, Kaname ^a   Miyazaki, Miki ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Ichimura, Yohei ^a   Noda, Shinji ^a   Kuwano, Yoshihiro ^a   Yanaba, Koichi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Ambrisentan; Cyanosis; Raynaud's phenomenon; Systemic sclerosis; Thermography

Indexed keywords

ALPHA CYCLODEXTRIN; ALPHA TOCOPHEROL NICOTINATE; AMBRISENTAN; BERAPROST; LIMAPROST; SARPOGRELATE; TOCOPHEROL; ENDOTHELIN A RECEPTOR ANTAGONIST; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CYANOSIS; DRUG EFFICACY; EDEMA; FEMALE; HUMAN; MIDDLE AGED; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; CASE REPORT; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

AGED; ENDOTHELIN A RECEPTOR ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; PHENYLPROPIONATES; PYRIDAZINES; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84938528332     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.885377     Document Type: Article

References (19)

1. Asano Y. Future treatments in systemic sclerosis . J Dermatol. 2010;37(1):54-70.
2. Horn A, Distler JH. Vascular alterations upon activation of TGFbeta signaling in fibroblasts-implications for systemic sclerosis . Arthritis Res Ther. 2010 ; 12(3) : 125.
3. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989-2003.
4. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM . Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol. 1994;21(10):1838-44.
5. Spieker LE, Noll G, Ruschitzka FT, Luscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol. 2001;37(6):1493-505.
6. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al . Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985-93.
7. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al . Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32-8.
8. Saggar R, Khanna D, Shapiro S, Furst DE, Maranian P, Clements P, et al. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study. Arthritis Rheum. 2012;64(12):4072-7.
9. Parisi S, Peroni CL, Lagana A, Scarati M, Ambrogio F, Bruzzone M, Fusaro E. Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study. Rheumatology (Oxford). 2013;52(6):1142-4.
10. O'Reilly D, Taylor L, el-Hadidy K, Jayson MI . Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis. Ann Rheum Dis. 1992;51(11):1193-6.
11. Shapiro S, Pollock DM, Gillies H, Henig N, Allard M, Blair C, et al . Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol. 2012;110(9):1373-7.
12. Opitz CF, Ewert R, Kirch W, Pittrow D . Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J. 2008;29(16):1936-t8.
13. Opitz CF, Ewert R . Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Eur J Clin Invest. 2006;36 Suppl 3:1-9.
14. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol. 1995;79(6):2122-31.
15. Tilton RG, Munsch CL, Sherwood SJ, Chen SJ, Chen YF, Wu C, et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther. 2000;13(2):87-97.
16. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med. 1999;160(2):600-7.
17. Gunther A, Enke B, Markart P, Hammerl P, Morr H, Behr J, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J. 2007;29(4):713-9.
18. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641-9.
19. Vizza CD, Fedele F, Pezzuto B, Rubin LJ. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf. 2012;11(6):1003-11.